

# CONTENTS

## ENVIRONMENTAL HEALTH CRITERIA FOR FUMONISIN B<sub>1</sub>

PREAMBLE	viii
ABBREVIATIONS	xvii
INTRODUCTION	xix
1. SUMMARY, EVALUATION AND RECOMMENDATIONS	1
1.1 Summary	1
1.1.1 Identity, physical and chemical properties, and analytical methods	1
1.1.2 Sources of human exposure	1
1.1.3 Environmental transport, distribution and transformation	1
1.1.4 Environmental levels and human exposure	2
1.1.5 Kinetics and metabolism in animals	2
1.1.6 Effects on animals and <i>in vitro</i> test systems	2
1.1.7 Effects on humans	3
1.1.8 Effects on other organisms in the laboratory	3
1.2 Evaluation of human health risks	4
1.2.1 Exposure	4
1.2.2 Hazard identification	4
1.2.3 Dose-response assessment	6
1.2.4 Risk characterization	6
1.3 Recommendations for protection of human health	6
2. IDENTITY, PHYSICAL AND CHEMICAL PROPERTIES, AND ANALYTICAL METHODS	8
2.1 Identity	8
2.2 Physical and chemical properties of the pure substance	9
2.3 Analytical methods	10
2.3.1 Sampling and preparation procedures	10

2.3.2	Extraction .....	10
2.3.3	Analysis .....	12
3.	SOURCES OF HUMAN EXPOSURE .....	14
4.	ENVIRONMENTAL TRANSPORT, DISTRIBUTION AND TRANSFORMATION .....	19
5.	ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE .....	20
6.	KINETICS AND METABOLISM IN ANIMALS .....	24
6.1	Absorption .....	24
6.2	Distribution .....	25
6.3	Elimination, excretion and metabolic transformation .....	26
6.4	Retention and turnover .....	28
6.5	Reaction with body components .....	29
7.	EFFECTS ON LABORATORY MAMMALS AND <i>IN VITRO</i> TEST SYSTEMS .....	30
7.1	Laboratory animals and <i>in vitro</i> test systems .....	30
7.1.1	Single exposure .....	30
7.1.2	Repeated exposure .....	30
7.1.2.1	Body weight loss .....	30
7.1.2.2	Hepatocarcinogenicity and nephrotoxicity .....	32
7.1.2.3	Immunotoxicity .....	36
7.1.3	Skin and eye irritation .....	37
7.1.4	Reproductive toxicity, embryotoxicity and teratogenicity .....	37
7.1.5	Mutagenicity and related end-points .....	41
7.1.6	Carcinogenicity .....	42
7.1.6.1	Carcinogenicity bioassays .....	42
7.1.6.2	Short-term assays for carcinogenicity .....	48
7.2	Other mammals .....	50
7.2.1	Equine leukoencephalomalacia .....	50

7.2.2	Porcine pulmonary oedema syndrome . . . .	53
7.2.3	Poultry toxicity . . . . .	56
7.2.4	Non-human primate toxicity . . . . .	57
7.2.5	Other species . . . . .	57
7.3	Mechanisms of toxicity – mode of action . . . . .	58
7.3.1	Disruption of sphingolipid metabolism . . .	58
7.3.1.1	Sphingolipids and their metabolism . . . . .	58
7.3.1.2	Fumonisin-induced disruption of sphingolipid metabolism <i>in vitro</i> .	59
7.3.1.3	Fumonisin disruption of sphingolipid metabolism <i>in vivo</i> .	64
7.3.1.4	Tissue and species specificity . . . .	68
7.3.1.5	Fumonisin-induced sphingolipid alterations: effects on growth, differentiation and cell death . . . .	69
7.3.1.6	Sphingolipid-mediated cellular deregulation and fumonisin diseases . . . . .	74
7.3.2	Altered fatty acid metabolism in liver . . . .	76
7.3.3	Other biochemical changes . . . . .	77
7.4	Factors modifying toxicity; toxicity of metabolites	79
8.	EFFECTS ON HUMANS . . . . .	82
8.1	Transkei, South Africa . . . . .	82
8.2	China . . . . .	84
8.3	Northern Italy . . . . .	85
9.	EFFECTS ON OTHER ORGANISMS IN THE LABORATORY . . . . .	86
9.1	Microorganisms . . . . .	86
9.2	Plants . . . . .	86
9.2.1	Duckweed and jimsonweed . . . . .	86
9.2.2	Tomato . . . . .	87
9.2.3	Maize . . . . .	87
10.	FURTHER RESEARCH . . . . .	88

11. PREVIOUS EVALUATIONS BY INTERNATIONAL ORGANIZATIONS .....	89
REFERENCES .....	90
APPENDIX 1. NATIONAL GUIDELINES FOR FUMONISINS .....	126
APPENDIX 2. NATURAL OCCURRENCE OF FUMONISIN B <sub>1</sub> (FB <sub>1</sub> ) IN MAIZE-BASED PRODUCTS .....	127
RESUME, EVALUATION ET RECOMMANDATIONS .....	135
RESUMEN, EVALUACION Y RECOMENDACIONES .....	143